Timolol

Generic Name: Timolol

Brand Names: Azarga, Betimol, Combigan, Cosopt, Duotrav, Istalol, Timoptic, Xalacom

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₂₄N_₄O_₃S

CAS Number: 26839-75-8

Unique Ingredient Identifier: 5JKY92S7BR

Background: Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.

Indication: Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure. In certain cases, timolol is used in the prevention of migraine headaches.

Associated Conditions: Increased Intra Ocular Pressure (IOP), Migraine, Ocular Hypertension, Open Angle Glaucoma (OAG)

Clinical Trials

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Ocular Hypertension
Open-angle Glaucoma

Interventions: Drug: AR-13324 Ophthalmic Solution 0.02%
Drug: Timolol Maleate Ophthalmic Solution 0.5% BID
Other: Placebo

First Posted Date: 2015-09-24

Last Posted Date: 2018-04-06

Lead Sponsor: Aerie Pharmaceuticals

Target Recruit Count: 708

Registration Number: NCT02558374

Locations: 🇺🇸
Aerie Pharmaceuticals, Bedminster, New Jersey, United States

Pupillary Response After Glaucoma Medication

Not Applicable

Completed

Conditions: Drug Effect (Glaucoma Drugs)

Interventions: Drug: Latanoprost
Drug: Timolol
Drug: Dorzolamide

First Posted Date: 2015-08-13

Last Posted Date: 2015-08-13

Lead Sponsor: Glostrup University Hospital, Copenhagen

Target Recruit Count: 21

Registration Number: NCT02522039

Locations: 🇩🇰
Glostrup University Hospital, Glostrup, Denmark

Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)

Phase 2

Completed

Conditions: Telangiectasia, Hereditary Hemorrhagic
Osler Rendu Disease

Interventions: Drug: Timolol nasal spray
Drug: Placebo nasal spray

First Posted Date: 2015-06-30

Last Posted Date: 2021-10-19

Lead Sponsor: Hospices Civils de Lyon

Target Recruit Count: 58

Registration Number: NCT02484716

Locations: 🇫🇷
Hospices Civils de Lyon - Hôpital Femme Mère Enfant / Service de génétique Clinique, Bron, France

Topical Timolol Benefit in Venous Ulcers

Phase 2

Completed

Conditions: Venous Leg Ulcers

Interventions: Drug: Timolol
Other: Local care treatment

First Posted Date: 2015-04-21

Last Posted Date: 2018-08-03

Lead Sponsor: Centre Hospitalier Universitaire, Amiens

Target Recruit Count: 42

Registration Number: NCT02422017

Locations: 🇫🇷
CHU Amiens, Amiens, France

Stop Retinal Ganglion Cell Dysfunction Study

Phase 3

Completed

Conditions: Glaucoma

Interventions: Drug: Latanoprost
Drug: Bimatoprost
Drug: Travoprost
Drug: Timolol
Drug: Dorzolamide
Drug: Brinzolamide
Drug: Acetazolamide
Drug: Methazolamide

First Posted Date: 2015-03-17

Last Posted Date: 2024-10-10

Lead Sponsor: University of Miami

Target Recruit Count: 500

Registration Number: NCT02390284

Locations: 🇺🇸
Bascom Palmer Eye Institute - University of Miami, Miami, Florida, United States

Dose-Ranging Study of the Bimatoprost Ocular Insert

Phase 2

Completed

Conditions: Primary Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Bimatoprost
Drug: Timolol 0.5%
Device: Placebo Ocular Insert
Drug: Placebo Eye Drops

First Posted Date: 2015-02-09

Last Posted Date: 2020-06-04

Lead Sponsor: ForSight Vision5, Inc.

Target Recruit Count: 156

Registration Number: NCT02358369

Locations: 🇺🇸
Vold Vision, Fayetteville, Arkansas, United States
🇺🇸
Total Eye Care, Memphis, Tennessee, United States
🇺🇸
University of Eye Specialists, Maryville, Tennessee, United States

and more 7 locations

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Ocular Hypertension
Glaucoma

Interventions: Drug: OTX-TP
Drug: Timolol

First Posted Date: 2014-12-09

Last Posted Date: 2016-12-14

Lead Sponsor: Ocular Therapeutix, Inc.

Target Recruit Count: 72

Registration Number: NCT02312544

Locations: 🇺🇸
Vold Vision, Fayetteville, Arkansas, United States

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Ocular Hypertension
Glaucoma, Open-Angle

Interventions: Drug: Bimatoprost SR
Drug: Timolol Vehicle (placebo)

First Posted Date: 2014-09-26

Last Posted Date: 2021-07-28

Lead Sponsor: Allergan

Target Recruit Count: 528

Registration Number: NCT02250651

Locations: 🇨🇦
Sunnybrook Research Institute, Toronto, Ontario, Canada
🇺🇸
Mark B. Kislinger, MD, Inc., Glendora, California, United States
🇺🇸
Southern California Eye Physicians and Surgeons, Los Alamitos, California, United States

and more 110 locations

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: Bimatoprost SR
Drug: Timolol Vehicle (placebo)

First Posted Date: 2014-09-25

Last Posted Date: 2020-06-11

Lead Sponsor: Allergan

Target Recruit Count: 594

Registration Number: NCT02247804

Locations: 🇺🇸
Nature Coast Clinical Research, Crystal River, Florida, United States
🇺🇸
Montebello Medical Eye Center Inc., Montebello, California, United States
🇺🇸
Glaucoma Institute of Beverly Hills, Los Angeles, California, United States

and more 103 locations

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Ocular Hypertension
Glaucoma

Interventions: Drug: AR-13324 Ophthalmic Solution 0.02%
Drug: AR-13324 Ophthalmic Solution 0.02% BID
Drug: Timolol maleate Ophthalmic Solution 0.5% BID
Other: Placebo

First Posted Date: 2014-09-23

Last Posted Date: 2018-04-06

Lead Sponsor: Aerie Pharmaceuticals

Target Recruit Count: 93

Registration Number: NCT02246764

Locations: 🇺🇸
Nancy Ramirez, Bedminster, New Jersey, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy